Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Phibro Animal Health (PAHC) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Phibro Animal Health (PAHC) over the last 13 years, with Q2 2025 value amounting to $279.0 million.

  • Phibro Animal Health's Accumulated Depreciation & Amortization rose 1369.69% to $279.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $279.0 million, marking a year-over-year increase of 1369.69%. This contributed to the annual value of $279.0 million for FY2025, which is 1369.69% up from last year.
  • As of Q2 2025, Phibro Animal Health's Accumulated Depreciation & Amortization stood at $279.0 million, which was up 1369.69% from $245.4 million recorded in Q2 2024.
  • In the past 5 years, Phibro Animal Health's Accumulated Depreciation & Amortization registered a high of $279.0 million during Q2 2025, and its lowest value of $223.1 million during Q2 2021.
  • For the 5-year period, Phibro Animal Health's Accumulated Depreciation & Amortization averaged around $250.4 million, with its median value being $245.4 million (2024).
  • Per our database at Business Quant, Phibro Animal Health's Accumulated Depreciation & Amortization plummeted by 693.1% in 2024 and then skyrocketed by 1369.69% in 2025.
  • Phibro Animal Health's Accumulated Depreciation & Amortization (Quarter) stood at $223.1 million in 2021, then rose by 8.03% to $241.0 million in 2022, then increased by 9.4% to $263.6 million in 2023, then decreased by 6.93% to $245.4 million in 2024, then rose by 13.7% to $279.0 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $279.0 million for Q2 2025, versus $245.4 million for Q2 2024 and $263.6 million for Q2 2023.